Incyte (WBO:INCY) Other Stockholders Equity

: €0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Incyte's Other Stockholders Equity for the quarter that ended in Dec. 2023 was €0 Mil.

Incyte's quarterly Other Stockholders Equity declined from Jun. 2023 (€-0 Mil) to Sep. 2023 (€-0 Mil) but then increased from Sep. 2023 (€-0 Mil) to Dec. 2023 (€0 Mil).

Incyte's annual Other Stockholders Equity declined from Dec. 2021 (€0 Mil) to Dec. 2022 (€-0 Mil) but then increased from Dec. 2022 (€-0 Mil) to Dec. 2023 (€0 Mil).

Incyte Other Stockholders Equity Historical Data

The historical data trend for Incyte's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Stockholders Equity																-	-	-	-	-

Incyte Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Incyte Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Incyte's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.